Skip to Content


Active Substance: fluticasone furoate
Common Name: fluticasone furoate
ATC Code: R01AD12
Marketing Authorisation Holder: Glaxo Group Ltd.
Active Substance: fluticasone furoate
Status: Withdrawn
Authorisation Date: 2008-10-06
Therapeutic Area: Rhinitis, Allergic, Seasonal Rhinitis, Allergic, Perennial
Pharmacotherapeutic Group: Nasal preparations

Therapeutic Indication

Adults, adolescents (12 years and over) and children (6 - 11 years). Alisade is indicated for the treatment of the symptoms of allergic rhinitis.

The marketing authorisation for Alisade has lapsed because it has not been marketed in the European Union in the three years following the granting of the authorisation.

Source: European Medicines Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.